Niagen Bioscience (NAGE) Other Non Operating Income (2016 - 2018)
Niagen Bioscience (NAGE) posted quarterly Other Non Operating Income of -$65000.0 for Q2 2018, up 79.24% quarter-over-quarter from -$313099.0 in Q3 2016.
Powered by 
Analysis
Niagen Bioscience (NAGE) Other Non Operating Income (2016 - 2018) Analysis & Trends
Niagen Bioscience (NAGE) has reported Other Non Operating Income for 2 consecutive years, with -$65000.0 the latest figure, recorded in Q2 2018.
- In Q2 2018, Other Non Operating Income changed N/A year-over-year to -$65000.0; the TTM figure through Dec 2018 stood at -$65000.0 (changed N/A YoY), while the FY2018 annual figure was -$65000.0, changed N/A from the prior year.
- Other Non Operating Income climbed to -$65000.0 in Q2 2018 per NAGE's latest filing, from -$313099.0 in the prior quarter.
- Across five years, Other Non Operating Income topped out at -$65000.0 in Q2 2018 and bottomed at -$313099.0 in Q3 2016.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Niagen Bioscience | 251.05 Mn | 184.31 Mn | 19.31 Mn |